Brief: Paxmedica Acquires Suramin Research Assets From Rediscovery Life Sciences To Accelerate NDA Submission For Pax-101
31/10/2023 12:01
Oct 31 (Reuters) - PaxMedica Inc PXMD.O :
* PAXMEDICA ACQUIRES SURAMIN RESEARCH ASSETS FROM
REDISCOVERY LIFE
SCIENCES TO ACCELERATE NDA SUBMISSION FOR PAX-101
* PAXMEDICA INC- REMAINS FIRMLY ON TRACK TO MEET CMC
MANUFACTURING
PRODUCTION REQUIREMENTS FOR PAX-101 IN FIRST HALF OF 2024
Source text for Eikon: ID:nGNX3855ly
Further company coverage: PXMD.O
Recent news on Kuvatris Therapeutics
See all newsBrief: PaxMedica Responds To Emergency Request For IV Suramin And Commits To Provide Immediate Access To PAX-101
PaxMedica rises on Malawi's request for access to sleeping sickness drug
Brief: Paxmedica Receives Emergency Request For Iv Suramin From African Health Ministry For Use In Treating Fatal Sleeping Sickness
Brief: PaxMedica Achieves Key Milestone In The Development Of PAX-101 And Provides Update On Potential NDA Submission
Brief: Paxmedica Announces Pricing Of $7.0 Million Public Offering